Categories
Loading...
Categories
Bliss GVS Pharma has announced a closure of the trading window starting April 1, 2025, affecting insiders and designated persons until 48 hours post the release of the audited financial results for the financial year ending March 31, 2025. This measure is implemented to ensure compliance with insider trading regulations. Investors should view this as a routine procedural step, but it may create a temporary reduction in trading activity which could affect short-term market dynamics. A positive outlook could follow upon the release of the financial results.